CD5 and neoplasm: Tumor growth was monitored once a week by measuring the percentage of CD5 + /CD7 + tumor cells in the peripheral blood and by in vivo imaging to detect luciferase-expressing cells; for ethical reasons, mice were sacrificed when circulating CD5 + /CD7 + cells reached 40% of the total PBMC population.